Your email has been successfully added to our mailing list.

×
0 0.000715819613457393 0.00214745884037231 0.00357909806728709 -0.000572655690765864 0.000715819613457393 0.000715819613457393 0.00787401574803158
Stock impact report

CorMedix: Waiting On Phase III ReSPECT For A Further Re-Rating (Upgrade) [Seeking Alpha]

CorMedix Inc. (CRMD) 
NASDAQ:AMEX Investor Relations: cormedix.com
Company Research Source: Seeking Alpha
CRMD's FY25 saw strong profitability: $163.1M net income, $401.3M pro forma revenue, and $77.2M adjusted EBITDA, aided by the Melinta acquisition. CRMD stock trades at discounted multiples (8.43x P/E, 4.38x EV/EBITDA), reflecting execution risk and conservative growth assumptions despite robust cash flow. The ReSPECT trial could unlock a $2B prophylaxis market and drive a CRMD stock valuation re-rating if results are positive. Tingting Ji/iStock via Getty Images Thesis CorMedix Inc. ( CRMD ) stock has been on the downward slope since early January. Shares hit a mid-$6 low in late March and have seen some slight upside into the $7 range. In my previous Show less Read more
Impact Snapshot
Event Time:
CRMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for CRMD alerts
Opt-in for
CRMD alerts

from News Quantified
Opt-in for
CRMD alerts

from News Quantified